To decipher potential synergistic treatment effects by combining ERBB2 and anti-PD-1 blockade, we performed a preclinical study in an autochthonous mouse model of SCLC, in which tumors are induced upon Cre-mediated biallelic deletion of Rb1 and Trp53. We recorded the clinicopathologic parameters of SCLC bearing mice listed according to the applied therapy regimens. This evidence concerns the gene RB1 and small cell lung carcinoma.